Home / Pharmaceuticals / Hemophilia Treatment Market By Product (Plasma Derived and Recombinant Coagulation Factor Concentrates, Antifibrinolytic Agents, Desmopressin), By Type (Hemophilia A, Hemophilia B, Others) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

Hemophilia Treatment Market By Product (Plasma Derived and Recombinant Coagulation Factor Concentrates, Antifibrinolytic Agents, Desmopressin), By Type (Hemophilia A, Hemophilia B, Others) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

Published: Aug 2017 | Report Code: 58640-08-17

Hemophilia is a genetic bleeding disorder caused due to deficiency or missing protein needed for clotting, due to which the normal blood clotting does not occur. The episodes of bleeding depends on the severity of hemophilia. There are two main forms of hemophilia namely Hemophilia A and Hemophilia B. Hemophilia A is approximately four times more prevalent than hemophilia B. Incidence of hemophilia A is one in five thousand live male births. Though the studies about world incidence of hemophilia are not that well known, but approximately four lakh people suffer from it. Around seventy five percent people with hemophilia does not receive adequate treatment or have no access to any form of treatment. The major growth drivers for hemophilia treatment market include rising diagnosis rate, increase focus on prophylactic treatment and development of novel treatment.

The report titled “Hemophilia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall hemophilia treatment market along with the market size and estimates for the duration 2015 to 2025. The said research study covers in-depth analysis of multiple market segments based on type of product, type of hemophilia and different geographies. The product types studied for analyzing the overall global hemophilia treatment market are majorly segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents and desmopressin. The global hemophilia treatment market is segmented by hemophilia type into Hemophilia A, Hemophilia B and others.

Geographically, the global hemophilia treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East and Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa 

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year. Further cross-sectional presented in terms of product, hemophilia type and constituent region/country level markets is also included in this section. 

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global hemophilia treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global hemophilia treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global hemophilia treatment market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report. 

Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the hemophilia treatment market. The key players profiled in this report are Baxter International, Inc., Baxalta, Bayer AG, Biogen Idec, Inc., Chugai Pharmaceutical Co., CSL Behring, Genentech, Inc., Hospira, Inc., Ferring B.V., Kedrion, Octapharma AG, Novo Nordisk, Pfizer, Inc., Sanofi SA, Swedish Orphan Biovitrum AB, Shire Plc. and others.

Hemophilia Treatment Market

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Hemophilia Treatment Market Portraiture
2.1.1. Global Hemophilia Treatment Market, by Product Type, 2016
2.1.2. Global Hemophilia Treatment Market, by Hemophilia Type, 2016
2.1.3. Global Hemophilia Treatment Market, by Geography, 2016

Chapter 3. Hemophilia Treatment: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.4.1. Attractive Investment Proposition, by Geography
3.5. Competitive Landscape
3.5.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Hemophilia Treatment Market, by Product Type, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Hemophilia Treatment Market, by Product Type
4.3. Plasma Derived Coagulation Factor Concentrates
4.3.1. Factor VIII
4.3.2. Factor IX
4.3.3. Combination
4.4. Recombinant Coagulation Factor Concentrates
4.4.1. Factor VIII
4.4.2. Factor IX
4.4.3. Combination
4.5. Antifibrinolytic Agents
4.6. Desmopressin

Chapter 5. Global Hemophilia Treatment Market, by Hemophilia Type, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. Attractive Investment Proposition: Global Hemophilia Treatment Market, by Hemophilia Type
5.3. Hemophilia A
5.4. Hemophilia B
5.5. Others

Chapter 6. Global Hemophilia Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Hemophilia Treatment Market Analysis, 2015 – 2025
6.2.1. North America Hemophilia Treatment Market, by Product Type, 2015 – 2025 (US$ Mn)
6.2.2. North America Hemophilia Treatment Market, by Hemophilia Type, 2015 – 2025 (US$ Mn)
6.2.3. North America Hemophilia Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Hemophilia Treatment Market Analysis, 2015 – 2025
6.3.1. Europe Hemophilia Treatment Market, by Product Type, 2015 – 2025 (US$ Mn)
6.3.2. Europe Hemophilia Treatment Market, by Hemophilia Type, 2015 – 2025 (US$ Mn)
6.3.3.
6.3.4. Europe Hemophilia Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.3.4.1. U.K.
6.3.4.2. Germany
6.3.4.3. France
6.3.4.4. Rest of Europe
6.4. Asia Pacific Hemophilia Treatment Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Hemophilia Treatment Market, by Product Type, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Hemophilia Treatment Market, by Hemophilia Type, 2015 – 2025 (US$ Mn)
6.4.3. Asia Pacific Hemophilia Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. India
6.4.3.4. Rest of APAC
6.5. Latin America Hemophilia Treatment Market Analysis, 2015 – 2025
6.5.1. Latin America Hemophilia Treatment Market, by Product Type, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Hemophilia Treatment Market, by Hemophilia Type, 2015 – 2025 (US$ Mn)
6.5.3. Latin America Hemophilia Treatment Market, by Country, 2015 – 2025 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Hemophilia Treatment Market Analysis, 2015 – 2025
6.6.1. MEA Hemophilia Treatment Market, by Product Type, 2015 – 2025 (US$ Mn)
6.6.2. MEA Hemophilia Treatment Market, by Hemophilia Type, 2015 – 2025 (US$ Mn)
6.6.3. MEA Hemophilia Treatment Market, by Region, 2015 – 2025 (US$ Mn)
6.6.3.1. UAE
6.6.3.2. Saudi Arabia
6.6.3.3. South Africa
6.6.3.4. Rest of MEA

Chapter 7. Company Profiles
7.1. Baxter International, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Baxalta
7.3. Bayer AG
7.4. Biogen Idec, Inc.
7.5. Chugai Pharmaceutical Co.
7.6. CSL Behring
7.7. Genentech, Inc.
7.8. Hospira, Inc.
7.9. Ferring B.V.
7.10. Kedrion
7.11. Octapharma AG
7.12. Novo Nordisk
7.13. Pfizer, Inc.
7.14. Sanofi SA
7.15. Swedish Orphan Biovitrum AB
7.16. Shire Plc.
7.17. Other Notable Players 

List of Tables

TABLE 1 Global Hemophilia Treatment Market, by Product Type, 2015 – 2025 (US$ Mn)
TABLE 2 North America Hemophilia Treatment Market, by Product Type, 2015 – 2025 (US$ Mn)
TABLE 3 North America Hemophilia Treatment Market, by Hemophilia Type, 2015 – 2025 (US$ Mn)
TABLE 4 North America Hemophilia Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 5 Europe Hemophilia Treatment Market, by Product Type, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Hemophilia Treatment Market, by Hemophilia Type, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Hemophilia Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Hemophilia Treatment Market, by Product Type, 2015 – 2025(US$ Mn)
TABLE 9 Asia Pacific Hemophilia Treatment Market, by Hemophilia Type, 2015 – 2025(US$ Mn)
TABLE 10 Asia Pacific Hemophilia Treatment Market, by Country, 2015 – 2025(US$ Mn)
TABLE 11 Latin America Hemophilia Treatment Market, by Product Type, 2015 – 2025(US$ Mn)
TABLE 12 Latin America Hemophilia Treatment Market, by Hemophilia Type, 2015 – 2025(US$ Mn)
TABLE 13 Latin America Hemophilia Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 14 Middle East and Africa Hemophilia Treatment Market, by Product Type, 2015 – 2025 (US$ Mn)
TABLE 15 Middle East and Africa Hemophilia Treatment Market, by Hemophilia Type, 2015 – 2025 (US$ Mn)
TABLE 16 Middle East and Africa Hemophilia Treatment Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 17 Baxter International, Inc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 18 Baxalta: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 19 Bayer AG: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 20 Biogen Idec, Inc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 21 Chugai Pharmaceutical Co.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 22 CSL Behring: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 23 Genentech, Inc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 24 Hospira, Inc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 25 Ferring B.V: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 26 Kedrion: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 27 Octapharma AG: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 28 Novo Nordisk: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 29 Pfizer, Inc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 30 Sanofi SA: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 31 Swedish Orphan Biovitrum AB: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)
TABLE 32 Shire Plc.: Company Snapshot (Business Description, Financial Information, Product Portfolio, Key Developments)

List of Figures

FIG. 1 Hemophilia Treatment : Market Segmentation
FIG. 2 Global Hemophilia Treatment Market, by Product Type, 2016 (US$ Mn)
FIG. 3 Global Hemophilia Treatment Market, by Hemophilia Type, 2016 (US$ Mn)
FIG. 4 Global Hemophilia Treatment Market Share, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Plasma Derived Coagulation Factor VIII Concentrates Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Plasma Derived Coagulation Factor IX Concentrates Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Plasma Derived Coagulation Combination Concentrates Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Recombinant Coagulation Factor VIII Concentrates Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Recombinant Coagulation Factor XI Concentrates Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Recombinant Coagulation Combination Concentrates Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Antifibrinolytic Agents Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global Desmopressin Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 15 U.S. Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 16 Canada Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 17 U.K. Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 18 Germany Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 19 France Hemophilia Treatment Market, 2015-2025 (US$ Mn)
FIG. 20 Rest of Europe Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 21 Japan Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 22 China Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 23 India Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 24 Rest of Asia Pacific Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 25 Brazil Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 26 Mexico Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 27 Rest of Latin America Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 28 UAE Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 29 Saudi Arabia Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 30 South Africa Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 31 Rest of Middle East and Africa Hemophilia Treatment Market, 2015 – 2025 (US$ Mn)

Based on the type of products, the global hemophilia treatment market is segmented as follows: 

  • Plasma Derived Coagulation Factor Concentrates
    • Factor VIII
    • Factor IX
    • Combination
  • Recombinant Coagulation Factor Concentrates
    • Factor VIII
    • Factor IX
    • Combination
  • Antifibrinolytic Agents
  • Desmopressin

With increase in healthcare expenditure, preference for prophylactic treatment, rise in diagnosis rate, significant rise in usage of recombinant coagulation factor are major contributors in growth of haemophilia market. In near future, recombinant coagulation factor concentrates would dominate the global haemophilia market. Recombinant coagulation factor are preferred by most of the physician thus anticipated to drive the haemophilia market in the given forecast period, due to low risk of blood borne infection. Plasma derived coagulation factor is anticipated to have slow CAGR during the forecast period due to high risk of blood associated infections and less availability of plasma derived from blood (lack of blood donors).

Hemophilia Treatment Market

Based on the type of hemophilia, the global hemophilia treatment market is segmented as follows: 

  • Hemophilia A
  • Hemophilia B
  • Others

Hemophilia is the most common blood disorder and is classified into two man types Hemophilia A and Hemophilia B. Hemophilia A, also called as classic hemophilia is the most common type, occurring due to deficiency of factor VIII levels. Hemophilia A is four times more prevalent than hemophilia B and thus dominates the global hemophilia treatment market. Rising prevalence of Hemophilia A and increasing on-demand Hemophilia A prophylactic would boost the global hemophilia market. Hemophilia B, also well known as Christmas disease, occurs due to factor IX deficiency. Hemophilia C occurs due to deficiency of factor XI. Acquired hemophilia is result of medication, illness or pregnancy. It is rarely observed and resolved with proper treatment.

Hemophilia Treatment Market

For the purpose of this study, the global hemophilia treatment market is geographically categorized into:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa

Hemophilia Treatment Market

In 2016, North America dominated the global hemophilia treatment market followed by Europe. The prevalence of hemophilia is around 134 cases per one million U.S. males. Rising prevalence of hemophilia, increasing healthcare expenditure, awareness about bleeding disorder, extensive research and development in diagnostic technology and treatment, and favorable reimbursement policies, are some of the major factors that fuel the growth of hemophilia treatment market in North America. Asia Pacific is anticipated to be the fastest growing market in the forecast period 2017-2025. Increase in incidence of hemophilia, rising awareness about disease, high disposable income, and improving healthcare infrastructure are important factors contributing to the growth of hemophilia market in Asia Pacific. In emerging economies such as China, India there is increasing funding by the government and research institute for technological advancement in diagnostics and treatment of hemophilia and increase in use of recombinant products thus exhibiting lucrative opportunity for Asia Pacific market.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients